Vicapsys Life Sciences, Inc. (VICP)
OTC Markets OTCPK
Fundamentals
Valuation and ratings
Vicapsys Life Sciences, Inc. trades at USD1.45. We do not hold enough of the inputs to run a discounted cash flow on this company, so we publish no fair value for it rather than a number we would not defend.
About Vicapsys Life Sciences, Inc.
Vicapsys Life Sciences, Inc. focuses on the development and commercialization of VICAPSYN, a proprietary product. The company's product is applied to transplantation therapies and related stem-cell applications in the transplantation field. It also develops VYBRIN, a product based on CXCL12 for prevention of post-surgical adhesions in abdominal surgery, coating of implantable medical devices and other implants to eliminate fibrosis, and wound healing with a focus on diabetic ulcers. The company was formerly known as Phage Therapeutics International, Inc. and changed its name to Vicapsys Life Sciences, Inc. in September 2017. Vicapsys Life Sciences, Inc. was incorporated in 1997 and is based in Suwanee, Georgia.
The full research page for VICP, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.